Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CRVSthis companyCorvus Pharmaceuticals, Inc.	$11.26	-40.53×	9.93×	0×	-39.82×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-69.1%	-5.4%	0.02×	0.24×	0×	6.21×	0.0%	2	32.84	2	C
CHRSCoherus Oncology, Inc.	$0.79	-0.98×	2.8×	4.05×	-0.72×	-124.2%	57.9%	-425.7%	-403.8%	-279.1%	-151.8%	-81.0%	0.66×	0.29×	-19.95×	1.46×	0.0%	2	-12.02	1	C-
CMPXCompass Therapeutics, Inc.	$0.81	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
CTMXCytomX Therapeutics, Inc.	$2.07	-28.4×	5.93×	7.71×	-36.76×	-283.4%	100.0%	-29.3%	-22.8%	-17.5%	-20.5%	-12.9%	0.04×	0.53×	0×	3.09×	0.0%	1	1.34	2	C
MGNXMacroGenics, Inc.	$2.41	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
NKTRNektar Therapeutics	$37.60	-4.35×	7.94×	12.91×	-6.18×	-172.6%	100.0%	-236.8%	-297.1%	-182.6%	-52.8%	-29.3%	1.66×	-0.98×	-4.99×	4.97×	0.0%	1	-1.18	2	C
Peer median	—	-4.35×	4.3×	4.05×	-6.18×	-172.6%	71.1%	-48.7%	-49.9%	-134.2%	-35.3%	-29.3%	0.66×	0.29×	-4.99×	4.97×	0.0%	1	-1.18	2	—